About: Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $144.34 (+1.55%)
PTGX NASDAQ Protagonist Therapeutics Inc
Protagonist Therapeutics Inc share price
Atividade de preço de PTGX
Último preço
$ 144,930
Variação (24h)
2,79 USD (1,96%)
Volume
118.72K
Volume (média 4 sem.)
-
Abertura
$ 144,03
Variação do dia
$ 142,87 - $ 146,44
Fechamento anterior
$ 142,14
Último negócio
29 Oct, 5:09 pm GMT+0
Atrasado
29 Oct, 5:09 pm GMT+0
PTGX price performance
Atrasado
29 Oct, 5:09 pm GMT+0
quote.marketSignals